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Introduction: The cyclooxygenases are a group of enzymes catalyzing the formation of prostaglandins from
arachidonic acid. Cyclooxygenase-1 (COX-1) is a constitutive form, thought to be a “housekeeping gene”, with constant
levels of expression in most tissues. COX-1 expression in the thyroid gland, except for medullary thyroid carcinoma, has
not been a subject of much interest. Cyclooxygenase-2 (COX-2) can be expressed in response to various stimuli, such
as mitogens, hormones, cytokines, growth factors. The product of COX-2 activity has been implicated in carcinogenesis.
Recent studies have shown that up-regulation of COX-2 is associated with numerous neoplasms. Hereby, we present a
study analysing COX-1 and COX-2 expression in papillary thyroid carcinoma (PTC), Hashimoto thyroiditis (HT) and
nontoxic nodular goitre (NNG) in fine needle aspiration biopsy (FNAB) washouts and in postoperative tissue.
Material and methods: Cytological specimens from 120 patients (105 females and 15 males) have been studied,
including patients with HT, PTC and NNG. Moreover, we have examined postoperative tissue specimens from 51
patients with PTC and NNG.
The methods of molecular analysis have included extraction of total RNA from FNAB cytological material and
postoperative tissues, spectrophotometric assessment of the RNA purity, cDNA synthesis in reverse transcription
reaction and an analysis of genes expression data by real-time PCR.
Results: The performed analysis has revealed statistically significant higher expression level of the COX-2 gene in
PTC group, in comparison with HT and NNG groups (in both cytological and postoperative material).
In PTC patients, COX-2 gene expression levels in the material obtained by FNAB were similar to those in the
postoperative thyroid tissue.
No correlations between COX-2 gene expression level and TNM staging in PTC samples have been observed.
There were no correlations between COX-2 expression and anti-TPO antibodies level, or patient’s sex or age in the
studied groups. Also, there were no correlations of COX-1 gene expression level among PTC, HT and NNG groups.
Conclusions: Our results suggest that COX-2 gene does not participate in the mechanisms involved in molecular
association of HT with PTC. However, in case of PTC itself, it may play some role in neoplastic transformation.
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The cyclooxygenases are a group of enzymes that catalyze
the formation of prostaglandins from arachidonic acid [1].
Cyclooxygenase 1 (COX-1) is a membrane-bound enzyme
present in many tissues and organs involved in the synthe-
sis of thromboxane A2 (TXA2) and prostacyclines (PGI2).
COX-1 gene is located on chromosome 9q and encodes a
66-kDa protein; its expression is constant in most tissues
and belongs to the so-called “housekeeping genes” [2].
COX-1 gene expression in the thyroid gland (except for
the medullary thyroid carcinoma [3,4] has not been a sub-
ject of interest. COX-2 gene is located on the long arm of
chromosome 1 (position lq25.2-q25.3), contains 10 exons
and encodes a protein of 70 kDa. COX-2, also called an
inducible isoform, is primarily identified with the body’s
response to stress factors and initiation of inflammation, its
expression is tightly controlled under basal conditions,
increases significantly in pathological conditions, under the
influence of cytokines, hormones, inflammatory mediators
and mitogens. It can inhibit apoptosis and induce prolifera-
tion of tumour cells, also the ability of these cells to form
metastases and invasion [5,6].
Increased COX-2 activity is associated with the occur-
rence of many different neoplasms such as squamous cell
carcinoma of the skin, lung, colorectal, breast, prostate,
pancreas, liver, stomach, skin, bladder and ovarian cancers.
In vivo models have shown that prostaglandins (PGs) -
produced in response to the action of the enzyme COX-
2 - are responsible for the stimulation of angiogenesis in
tumours, and the use of COX-2 inhibitors slows down
the process of neovascularization [7]. In addition, micro-
vessel density in tumours of the colon appears to be closely
related to the COX-2 gene expression level.
In recent decades, there is an increasing incidence of
thyroid cancer around the world [8]. On the other hand,
the effects of COX-2 enzyme in inflammatory processes
of the thyroid have recently become a subject of interest
for researchers. Additionally, the relationship between
Hashimoto thyroiditis and the incidence of thyroid cancer
is complex and not yet fully explained [9-11]. In the present
study, relative expression levels of COX-1 and COX-2 gene
in the fine needle aspiration biopsy (FNAB) washouts
and in postoperative tissue of patients with papillary
thyroid carcinoma (PTC), Hashimoto thyroiditis (HT) and
nontoxic nodular goitre (NNG) were evaluated. As far as
we are concerned, our present study includes the largest
group of HT patients extensively studied by molecular
methods.Materials and methods
The procedures were approved by the Ethical Committee
of the Medical University of Lodz (Poland). All patients
were informed and agreed to participate in this study.One hundred seventy one (171) thyroid specimens were
analyzed. Cytological specimens came from 120 patients,
and the tissue material - from 51 patients. There were
62 cases of papillary thyroid carcinoma (PTC), 56 cases
of Hashimoto’s thyroiditis (HT) and 53 cases of non-
toxic nodular goitre (NNG) collected from 28 men and
143 women. Patients ranged in age from 24 to 77 years
(median: 52 years for PTC group, 49 years for HT group,
57 years for NNG group).
Each aspirate was smeared for conventional cytology,
while the remaining part of aspirate was immediately
washed out of the needle. The cells, obtained from the
needle, were used for further investigation.
Tissue samples from the postoperative specimens of
PTC and NNG were obtained. Samples of macroscopically
unchanged thyroid tissue collected from patients with
nodular goitre served as an internal control for Real –time
experiment.
Total RNA was extracted using RNeasy Micro Kit (FNAB
material) and RNeasy Midi Kit (postoperative material)
(Qiagen, Hilden, Germany), based on modified Chomc-
zynski and Sacchi’s method [12]. RNA concentration was
spectrophotometrically assessed by measuring absorbance
at 260 and 280 nm (NanoDrop ND-1000 Spectrophotom-
eter, Thermo Fisher Scientific, USA).
Total RNA was reversely transcribed in a Mastercycler
personal thermal cycler (Eppendorf, Hamburg, Germany)
according to manufacturer’s procedures in a total volume
of 50 μL (TaqMan Reverse Trancriptase Reagents, Applied
Biosystems, Foster City, CA, USA).
The relative expression of COX-2 gene was assessed using
the ABI PRISM 7500 SDS Software (ABI PRISM 7500 Se-
quence Detection System, Applied Biosystems), according
to the manufacturer’s protocol. The PCR reactions for
COX-2 gene were run with 5 μL of cDNA in a total volume
of 50 μL, using TaqMan Universal PCR Master Mix (Ap-
plied Biosystems, Foster City, CA, USA) and predesigned
primer/probe set (Assays-on-Demand™, Gene Expression
assay, Hs 00153133_m1, Hs 00377721_m1 Applied Biosys-
tems). Amplification reactions were done in triplicate for
each examined sample.
Controls with no template cDNA were used with each assay.
The reference gene was ACTB (Assays-on-Demand™ Gene
Expression assay, Hs 99999903_m1, Applied Biosystems).
Cycling conditions were 50°C for 2 min and 95°C for
10 minutes, followed by 50 cycles at 95°C and 60°C for
1 minute. Macroscopically unchanged thyroid tissue served
as a calibrator to compare the relative amount of target in
different samples and to adjust for the plate-to-plate vari-
ation in amplification efficiency.
Data and statistical analysis
Statistical analysis was performed using statistical software
package Statistica 7.0. Basic measures of location (i.e.
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(SD), standard error of mean (SEM)] were calculated.
P values < 0.05 were considered to indicate statistical
significance.
Relative gene expression is determined by comparing
threshold cycle (Ct) for gene of interest (COX-2) with Ct
for the reference gene (β-actin) and was calculated using
the ΔΔCT method on an ABI PRISM® 7500 Sequence
Detection System Software (Applied Biosystems, Foster
City, CA, USA).
The data were statistically analyzed using a standard
parametric Student’s t-test, followed by non-parametric
Kruskal-Wallis one-way analysis of variance by ranks,
Tukey range test and non-parametric Mann–Whitney U
test.
Results
COX-2 mRNA expression was significantly higher in
PTC when compared with HT and NNG groups (FNAB
washouts) (p < 0.0001). The box-and-whisker plot dia-
grams, representing the expression levels of COX-2 (mean
and median values) in FNAB washouts, are presented in
Figures 1 and 2, respectively.
COX-2 expression was significantly higher in PTC when
compared to NNG group (postsurgical material) (p < 0.05)
(Figures 3 and 4).
In both PTC and NNG no significant differences in
COX-2 gene expression levels were found in the materialFigure 1 Box-and-whisker plots representing the COX-2 gene express
The results are calculated as RQ values. Whiskers represent mean ± SD (stan
(standard error of mean). The results were statistically analyzed by Kruskal-Wobtained from the FNAB, and in postoperative tissue
material (Student’s t-test, p > 0.05 in each case). The box-
and-whisker plot diagrams, representing the expression
levels of COX-2 (median and mean values) in FNAB and
in postsurgical PTC material, are presented in Figures 5
and 6, respectively (data for NNG not shown).
There was no correlation between COX-2 expression
and anti-TPO antibodies levels in the HT group. Also,
there were no correlations between COX-2 expression
and patient’s gender or age in both PTC and NNG
groups. Moreover, correlation between COX-2 gene ex-
pression level and pTNM staging in pT1a and pT2-T4
was not found (p > 0.05).
COX-1 expression occurred in all the test samples but
the recorded differences in the gene expression levels in
malignant and benign lesions, both in biopsy washouts
and in postoperative tissue, were - in contrast to COX-2
- not statistically significant (data not shown).
Discussion
The expression of mediators of inflammation in physio-
logical conditions and their role in the development of
neoplastic processes within the thyroid gland is not yet
fully clarified.
There have been several reports on an increased ex-
pression of COX-2 in different thyroid neoplasms. These
data suggest that the enzyme may play a role in the initi-
ation or progression of malignant tumours in the thyroidion by quantitative RT-PCR in NNG, PTC and HT groups (FNAB).
dard deviation) for particular groups. Boxes represent mean ± SEM
allis test (p < 0.0001).
Figure 2 Box-and-whisker plots representing the COX-2 gene expression by quantitative RT-PCR in NNG, PTC and HT groups (FNAB).
Results are calculated as RQ values. Whiskers represent mean ± SD (standard deviation) for particular groups. Boxes represent mean ± SEM
(standard error of mean). The results were statistically analyzed using the Kruskal-Wallis test (p < 0.0001).
Figure 3 Box-and-whisker plots representing the COX-2 gene expression by quantitative RT-PCR in PTC, NNG groups (post-surgical tissues).
Results are calculated as RQ values. Whiskers represent mean ± SD (standard deviation) for particular groups. Boxes represent lower quartile and upper
quartile. The results were statistically analyzed, using Man-Whitney U test (p < 0.05).
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Figure 4 Box-and-whisker plots representing the COX-2 gene expression by quantitative RT-PCR in PTC, NNG groups (post-surgical tissues).
Results are calculated as RQ values. Whiskers represent median and minimum and maximum values for particular groups. Boxes represent lower
quartile and upper quartile. The results were statistically analyzed, using Kruskal–Wallis test (p < 0.05).
Figure 5 Box-and-whisker plots, representing the expression of COX-2 gene in the studied groups (FNAB, post-surgical tissues).
The results are calculated as RQ values. Whiskers represent mean ± SD (standard deviation) for particular groups. Boxes represent mean ± SEM
(standard error of mean). The results were statistically analyzed, using Man-Whitney U test (p < 0.05).
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Figure 6 Box-and-whisker plots, representing the expression of COX-2 gene in the studied groups (FNAB, post-surgical tissues).
The results are calculated as RQ values. Whiskers represent median and minimum and maximum values for particular groups. Boxes represent lower
quartile and upper quartile. The results were statistically analyzed, using Man-Whitney U test (p < 0.05).
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cern evaluation of the COX-2 activity by immunohisto-
chemical approach, and only a few authors have used the
molecular biology methods.
In previously published reports, COX-2 expression was
found in tissue from patients with differentiated thyroid
carcinoma, HT and NNG [13-18]. Immunohistochemical
studies demonstrated a high level of COX-2 expression in
both the PTC and HT but low or negligible in the NNG
and normal thyroid follicular cells, suggesting a relation-
ship between an autoimmune disease and the process of
carcinogenesis.
The study of Lee et al. [19] has shown prominent ex-
pression of COX-2 in thyroiditis, as well as benign and
malignant thyroid nodules but not in normal thyroid tis-
sue. The authors also observed no correlation between
severity of PTC with or without metastasis. Because of the
similar intensity of COX-2 staining found in thyroiditis
and thyroid nodules, the authors concluded only little
probability that COX-2 expression is related to the pro-
gression of thyroid disease [19].
Specht et al. [20] revealed overexpression of COX-2 in
8 out of 10 cases of thyroid cancer, specific to tumour
cells but not to the surrounding stroma. They have
shown that COX-2 mRNA and protein were increased in
malignant thyroid nodules, when compared with benign
nodules and adjacent thyroid tissue.
In our study the COX-2 gene expression level was sig-
nificantly higher in cytological material collected frompatients with PTC when compared to NNG and HT and
significantly higher in the tissue material of PTC, com-
paring with NNG. In addition, in the present study the
expression of COX-2 in patients with HT proved to be
comparable with the expression in NNG.
The recent study of other authors suggests that the high
expression of COX-2 and low expression of KAI-1/CD82
are associated with increased tumour invasiveness [21].
The results of our research, similarly to previous literature
report [22], do not indicate a correlation between these
parameters. However, failing to confirm the existence of
such a correlation in our present investigation, can result
from a relatively small number of cases comprised in the
study. It should also be noted that in our research correl-
ation analysis related only to the size of the tumour in
TNM scale but without metastases, as there were none in
our group of patients.
Our results together with the previously published
studies [14,23,24] confirmed the validity of genetic ana-
lysis in FNAB derived material. In our present study, the
results of COX-2 expression in tissue and FNAB wash-
outs material were comparable. This observation confirms
the significance of genetic analysis of this material be-
ing usually not abundant (rather scarce), but sufficient
to analyze by means of ultrasensitive methods.
In the published medical reports we have not met at-
tempts to link the COX-2 gene expression and anti-TPO
levels. Only in one study, the presence of specific auto-
antibodies itself rather than their level (concentration),
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no relationship between the anti-TPO concentrations and
COX-2 gene expression levels of the patients studied.
In the available literature, we have not met so far any
attempt to link the COX-2 expression with patient’s
gender. Our study, however, has shown no statistically
significant relationship between the COX-2 expression
level and patient’s gender, although the significant dispar-
ity between the number of men (28) and women (143) in
the study group should be noted.
So far, only a few authors have tried to evaluate the
COX-1 expression in thyroid diseases. In clinical study
of Lee et al. [26], COX-1 expression was low and similar
in different thyroid conditions. Results obtained by us in
the present study proved to be consistent with the afore-
mentioned report. COX-1 expression occurred in all the
test samples but the differences in gene expression levels
in malignant and benign lesions in both cytological and
postoperative materials - in contrast to COX-2, were not
statistically significant.Conclusions
The present study confirms the validity of genetic ana-
lysis of material collected from FNAB. The new methods
of molecular biology are of a such sensitivity that they
allow for the precise assessment of gene expression, even
if a small amount of genetic material is accessible.
The obtained results suggest that COX-2 gene does not
participate in mechanisms involved in molecular associ-
ation of HT with PTC. However, in case of PTC itself,
COX-2 expression is not a sufficient factor to become a
marker of ongoing cancer in the thyroid, nevertheless, it
may play a role in neoplastic transformation.
Epidemiological and histological studies indicate a
relationship between thyroid neoplasms and Hashimoto
disease, between COX-2 activity and carcinogenesis, but
also the further need to search for connecting factors and
randomized controlled trials to assess the actual frequency
of co-occurrence of these disease entities and their mo-
lecular basis.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
KK-R designed and coordinated the study, carried out the molecular genetic
studies and drafted the manuscript. KW-D participated in performing molecular
studies. AC-M participated in performing molecular studies. AZ participated in
coordination of the study and helped to draft the manuscript. AL, the
senior author, wrote the manuscript. All authors read and approved the
final manuscript.Acknowledgements
The study was supported by the funds from the Medical University of Lodz
(Poland) -No. 502-03/1/107-03/502-14-087 and 503/1-107-03/503-01Author details
1Department of Endocrinology and Metabolic Diseases, Medical University of
Lodz, Rzgowska St. No. 281/289, 93-338 Lodz, Poland. 2Polish Mother’s
Memorial Hospital – Research Institute, Lodz, Poland.
Received: 20 October 2014 Accepted: 1 December 2014References
1. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action
for aspirin-like drugs. Nat New Biol 1971, 231:232–235.
2. Burdan F, Chałas A, Szumiło J: Cyclooxygenase and prostanoids - biological
implications. Postepy Hig Med Dosw (Online) 2006, 60:129–141.
3. Bell CD, Vidal S, Kovacs K, Horvath E, Rotondo F: An immunohistochemical
survey of nine cases of medullary carcinoma of thyroid including
reactivity for Cox-1 and Cox-2 enzymes. Endocr Pathol 2002, 13:331–340.
4. Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A: 15-
Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative
effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a
human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat
2006, 81:14–30.
5. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in
epithelial cells overexpressing prostaglandin endoperoxide synthase 2.
Cell 1995, 83:493–501.
6. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M:
Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor
growth in vivo. Lab Invest 1999, 79:1469–1477.
7. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA,
Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of
cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306–1311.
8. Ward EM, Jemal A, Chen A: Increasing incidence of thyroid cancer: is
diagnostic scrutiny the sole explanation? Future Oncol 2010, 6:185–188.
9. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H: Is
Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res
2007, 150:49–52.
10. Matesa-Anińá D, Matesa N, Dabelińá N, Kusińá Z: Coexistence of papillary
carcinoma and Hashimoto’s thyroiditis. Acta Clin Croat 2009, 48:9–12.
11. Mazokopakis EE, Tzortzinis AA, Dalieraki-Ott EI, Tsartsalis AN, Syros PK,
Karefilakis CM, Papadomanolaki MG, Starakis IK: Coexistence of Hashimoto’s
thyroiditis with papillary thyroid carcinoma. a retrospective study. Hormones
(Athens) 2010, 9:312–317.
12. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem
1987, 162:156–159.
13. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T,
Matsuzuka F, Matsuura N, Kuma K, Miyauchi A: Cyclooxygenase-2
expression in thyroid neoplasms. Histopathology 2003, 42:492–497.
14. Krawczyk-Rusiecka K, Wojciechowska-Durczyńska K, Cyniak-Magierska A,
Adamczewski Z, Gałecka E, Lewiński A: COX-2 expression in papillary thyroid
carcinoma (PTC) in cytological material obtained by fine needle aspiration
biopsy (FNAB). Thyroid Res 2011, 4:3.
15. Nose F, Ichikawa T, Fujiwara M, Okayasu I: Up-regulation of cyclooxygenase-2
expression in lymphotic thyroiditis and thyroid tumors. Am J Clin Pathol
2002, 117:546–551.
16. Siironen P, Ristimäki A, Narko K, Nordling S, Louhimo J, Andersson S,
Haapiainen R, Haglund C: VEGF-C and COX-2 expression in papillary
thyroid cancer. Endocr Relat Cancer 2006, 13:465–473.
17. Casey MB, Zhang S, Jin L, Kajita S, Lloyd RV: Expression of cyclooxygenase-2
and thromboxane synthase in non-neoplastic and neoplastic thyroid
lesions. Endocr Pathol 2004, 15:107–116.
18. Cornetta AJ, Russell JP, Cunnane M, Keane WM: Rothstein Cyclooxygenase-2
expression in human thyroid carcinoma and Hashimoto’s thyroiditis.
Laryngoscope 2002, 112:238–242.
19. Lee KJ, Jung YS, Kim WH, Yoon TI, Joo HJ, Soh EY: Cyclooxygenase-2
expression in human thyroid disease. J Endocrinol Invest 2008, 31:111–118.
20. Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey TJ 3rd:
Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab
2002, 87:358–363.
21. Scarpino S, Duranti E, Giglio S, Di Napoli A, Galafate D, Del Bufalo D, Desideri M,
Socciarelli F, Stoppacciaro A, Ruco L: Papillary carcinoma of the thyroid: high
Krawczyk-Rusiecka et al. Thyroid Research  (2014) 7:10 Page 8 of 8expression of COX-2 and low expression of KAI-1/CD82 are associated with
increased tumor invasiveness. Thyroid 2013, 23:1127–1137.
22. Garcia-Gonzales M, Abdulkader I, Vasquez Bouqete A, Neo XM, Forteza J,
Cameselle-Teijeiro J: Cyclooxygenase-2 in normal, hyperplastic and
neoplastic follicular cells of the human thyroid gland. Virchows Arch
2005, 447:12–17.
23. Wojciechowska-Durczyńska K, Krawczyk-Rusiecka K, Cyniak-Magierska A,
Zygmunt A, Gałecka E, Lewiński A: Relative quantification of PIK3CA
gene expression level in fine-needle aspiration biopsy thyroid specimens
collected from patients with papillary thyroid carcinoma and non-toxic
goitre by real-time RT-PCR. Thyroid Res 2010, 3:5.
24. Wojciechowska-Durczyńska K, Krawczyk-Rusiecka K, Cyniak-Magierska A,
Zygmunt A, Dedecjus M, Lewiński A: Is the PIK3CA gene expression in
FNAB washouts equivalent to that in postoperative tissue specimens
of papillary thyroid carcinoma? Neur Endocrinol Lett 2011, 32:59–63.
25. Karmisholt JS, Andersen S, Laurberg P: Variation in thyroid function in
subclinical hypothyroidism: importance for clinical follow-up and therapy.
Eur J Endocrinol 2011, 164:317–323.
26. Lee HM, Baek SK, Kwon SY, Jung KY, Chae SW, Hwang SJ, Woo JS, Lee JY:
Cyclooxygenase 1 and 2 expressions in the human thyroid gland.
Eur Arch Otorhinolaryngol 2006, 263:199–204.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
